Core Insights - The State-owned Assets Supervision and Administration Commission (SASAC) emphasizes the focus of central enterprises on nine strategic emerging industries and six future industries, indicating a significant shift in investment strategy [1] - Since the beginning of the 14th Five-Year Plan, central enterprises have invested 8.6 trillion yuan in strategic emerging industries, marking a substantial increase compared to the 13th Five-Year Plan [1] - There has been notable acceleration in development within sectors such as integrated circuits, biotechnology, and new energy vehicles, alongside breakthroughs in cutting-edge fields like humanoid robots and superconducting quantum computing [1] - The industrial foundation in areas like industrial mother machines and new materials has been strengthened, showcasing a new pattern of industry development characterized by tiered expansion and collaborative progress [1]

Group 1 - The investment promotion bureau's European representative office organized a delegation of technology companies from the UK, Belgium, Italy, and Hungary to conduct investment promotion activities in Tongling City [1] - Tongling city officials, including the mayor and party secretary, welcomed the European technology companies and introduced the city's open innovation history and thriving export-oriented economy [1] - During the investment environment promotion meeting, European companies expressed their willingness to invest and cooperate in China, showcasing projects from companies like A&B Smart Materials, Hyper Wind, and Clan Healthcare [1] Group 2 - The investment promotion bureau's deputy director emphasized the vast opportunities in the Chinese market for innovation and pledged to assist companies in their investment and cooperation efforts [1] - Tongling city maintains a highly open attitude towards international cooperation and aims to create an internationalized, market-oriented, and standardized business investment environment [1] - The European delegation visited the Tongling Economic and Technological Development Zone and learned about the development of new productive forces at local companies [2]

Market Overview - A-share market showed a fluctuating and differentiated trend, with major indices mostly declining while the Sci-Tech 50 Index rose against the trend, indicating resilience in the technology growth sector [1][2] - The Hong Kong stock market continued its upward trend, with the Hang Seng Technology Index slightly rising, driven by active performances in sectors like brain-computer interfaces and biotechnology [1][2] Index Performance - A-share indices experienced notable fluctuations, with the Shanghai Composite Index closing at 3856.45 points, down 0.1%, and the Shenzhen Component Index down 0.26% at 12971.8 points; the ChiNext Index fell 0.32% to 3056.3 points, influenced by the new energy industry chain [2] - The Sci-Tech 50 Index surged 1.52% to 1360.78 points, driven by hard technology sectors such as AI chips and computing infrastructure [2] - In the Hong Kong market, the Hang Seng Index rose 0.07% to 26465.87 points, while the Hang Seng Technology Index increased by 0.39% to 6067.05 points, marking three consecutive days of gains [2] Sector Highlights and Driving Logic - The A-share market exhibited a structural characteristic of "technology leading and consumption recovering," with policy-sensitive sectors and industrial transformation aligning [3] - The retail sector led gains, with the Wande Retail Index rising 1.36%, boosted by positive developments in U.S.-China trade talks regarding TikTok [3] - The electronics and computer sectors saw significant gains, with the GPU concept maintaining strength and the logic of domestic substitution for AI chips being reinforced [3] - In the Hong Kong market, technology growth and medical innovation drove performance, with brain-computer interface concepts experiencing a surge following product certifications [3] Underperforming Sectors and Driving Logic - A-share resource cyclical stocks and previously popular sectors collectively retreated, negatively impacting market sentiment; the non-ferrous metals sector fell 2.28% [4] - The lithium battery industry chain weakened for two consecutive days due to intensified competition and rising raw material costs [4] - In the Hong Kong market, cyclical and consumer sectors showed mixed performance, with the materials index dropping 2.96% due to industrial metal price corrections [4] Investment Strategy Recommendations - The current market is at a convergence of an "event vacuum period" and a "policy observation period," with cautious sentiment prevailing ahead of the Federal Reserve's meeting [5] - For A-shares, a focus on "technology independence and consumption recovery" is recommended, particularly in AI computing infrastructure and semiconductor equipment [6] - In the Hong Kong market, structural opportunities in "technology growth and medical innovation" should be seized, with attention on AI applications and core technology barriers [6]

Group 1 - Mirxes-B (2629.HK) experienced a significant price surge, rising over 35% to reach 75 HKD, marking a new all-time high since its IPO [1] - The company's market capitalization has surpassed 20 billion HKD [1] - Since its listing on May 23, the stock price has increased by 220% from the IPO price of 23.3 HKD [1] Group 2 - Mirxes is a Singapore-based company specializing in microRNA technology, focusing on making disease screening and diagnostic solutions accessible in key Asian markets [1] - The company was recently included in the Hang Seng Composite Index, effective from September 8, and has officially become a Hong Kong Stock Connect eligible stock [1]

基于公司结构代谢分析的药物发现平台，公司不仅推出了临床阶段候选产品ABP-671和ABP-745，更推 出了一系列临床前管线，包括AT6616、ABP-6016、ABP6118。 新元素药业是一家专注于代谢、炎症和心血管疾病疗法开发的生物技术公司。公司核心产品ABP-671是 一种URAT1抑制剂，正在中美进行2b/3期临床试验，有望成为一线痛风和高尿酸血症治疗药物。ABP- 671在治疗合并高尿酸血症CKD和难治性痛风方面也展现出临床前潜力。 新元素药业已向港交所提交上市申请，中信证券为其独家保荐人。 ...

Economic Indicators - In August, the industrial added value above designated size grew by 5.2% year-on-year, with a month-on-month increase of 0.37% [1] - From January to August, the industrial added value increased by 6.2% year-on-year [1] Policy Developments - New policies to promote private investment are being formulated, including minimum shareholding requirements for private investment in major projects in sectors like railways, nuclear power, and oil and gas pipelines [1] - Beijing's GDP is expected to exceed 5 trillion yuan by the end of the 14th Five-Year Plan in 2025 [1] Industry Innovations - Shanghai is accelerating the development and application of AI technologies in the high-end medical device industry, focusing on building a high-quality health corpus and promoting smart product upgrades [1] Corporate Actions - Xibei Restaurant Group announced adjustments to its menu, including using non-GMO soybean oil and preparing certain dishes fresh in-store by October 1, 2025 [2] - Xiaomi's upcoming smartphone series, renamed from Xiaomi 16 to Xiaomi 17, aims to compete directly with the iPhone [3] - 17 major automotive companies, including BYD and NIO, are committed to a payment initiative to enhance collaboration with suppliers [4] Market Trends - Nvidia is under investigation for violating antitrust laws related to its acquisition of Mellanox Technologies [3] - Tesla's German factory plans to increase production due to strong sales data [11] - Apple's first smart glasses are expected to launch within the next 12 to 16 months [7]

Group 1 - The South Korean government announced an increase in the National Growth Fund to 150 trillion KRW, with 75 trillion KRW sourced from pension funds, financial institutions, and private capital, and the remaining 75 trillion KRW established by the Korea Development Bank (KDB) for advanced strategic industry funding [1] - The National Growth Fund will support key industries aligned with President Lee Jae-myung's vision of becoming one of the top three AI nations, achieving a potential growth rate of 3%, and ranking among the world's top five economies, with specific allocations of 30 trillion KRW for AI, 20.9 trillion KRW for semiconductors, 15.4 trillion KRW for mobile transportation, 11.6 trillion KRW for biotechnology and vaccines, and 7.9 trillion KRW for secondary batteries [1] - The Vice Chairman of the Financial Services Commission emphasized that the fund will prioritize large projects that can create significant ripple effects in the industry and serve as turning points for economic growth, aiming to create a "Korean version of Nvidia" [1] Group 2 - The financial industry suggests that to ensure participation and sustainability of the fund, tax incentives and a robust management system should be established to enhance fund returns [1]

Core Viewpoint - Monte Rosa Therapeutics announced a collaboration with Novartis to develop novel molecular glue degraders (MGDs) for immune-mediated diseases, marking a significant advancement in their partnership and the potential for innovative treatments in this area [2][12][14]. Group 1: Collaboration Details - The collaboration is Monte Rosa's second agreement with Novartis, following a previous global exclusive license for the VAV1-directed degraders, including MRT-6160 [2][4]. - Monte Rosa will receive an upfront payment of $120 million, with the potential for up to $2.1 billion in development, regulatory, and sales milestone payments, as well as tiered royalties on global net sales [4][9]. - The agreement aims to accelerate the clinical development of MRT-6160 while allowing Monte Rosa to retain substantial value from the collaboration [4][12]. Group 2: Financial Aspects - The total deal value for the collaboration could reach $5.7 billion, which includes various milestone payments and royalties [9][12]. - Monte Rosa is eligible for a 30% share of profits and losses in the U.S. and tiered royalties outside the U.S. [4][9]. Group 3: Strategic Goals - The partnership is designed to expedite the development of MGDs targeting immune-mediated diseases, leveraging Monte Rosa's proprietary AI/ML-supported QuEEN™ platform and Novartis's capabilities [6][12][14]. - The collaboration aims to broaden the scope of clinical development and discover new insights for previously undruggable targets in cancer and neurological diseases [4][12]. Group 4: Technology and Innovation - Monte Rosa's QuEEN™ platform utilizes advanced AI/ML algorithms for rapid discovery and optimization of MGDs, supported by a growing library of compounds and specialized assays [16][23]. - The platform's capabilities include in silico discovery, structure-based design, and integrated proteomics to identify novel targets and enhance drug development [16][17][21].

Core Viewpoint - Mirxes-B (02629) has seen a significant stock price increase, rising over 150% from its IPO price of 23.3 HKD, reaching a high of 59.5 HKD, and currently trading at 54.75 HKD with a trading volume of 566 million HKD [1] Company Overview - Mirxes is a Singapore-based company specializing in microRNA (miRNA) technology, focusing on making disease screening and diagnostic solutions accessible in key Asian markets [1] - The company has one core product, GASTROClearTM, along with two other commercialized products, LUNGClearTM and FortitudeTM, and six candidates in preclinical stages [1] Product Details - GASTROClearTM is a blood-based miRNA detection kit consisting of 12 miRNA biomarkers for gastric cancer screening, which received Class C in vitro diagnostic (IVD) certification from the Health Sciences Authority (HSA) of Singapore in May 2019 and has been successfully commercialized in Singapore [1] Market Inclusion - Mirxes has been included in the Hang Seng Composite Index, effective from September 8, which has contributed to its stock price surge and its designation as a stock eligible for the Shanghai-Hong Kong Stock Connect [1]

中化新网讯 近日，中国科学院天津工业生物技术研究所在亚胺还原酶催化动态动力学拆分还原胺化合 成双手性中心N-取代氨基酰胺和氨基酯研究中取得新进展，为这类重要手性化合物的绿色高效合成提 供了新方法。 研究人员通过对亚胺还原酶酶库的筛选及蛋白质工程改造，获得了催化性能显著提升的突变体，该突变 体的催化效率较野生型酶提高了102倍。利用该工程酶，团队成功实现了抗癫痫药物布瓦西坦的克级规 模制备，并合成了一系列具有双手性中心的N-取代氨基酰胺、氨基酯及其内酰胺。通过晶体结构分析 与分子动力学模拟，研究人员揭示突变酶活性提高的机制。该研究为双手性中心氨基酸衍生物及其内酰 胺的高效、绿色不对称合成提供了新的生物催化策略，拓展了生物催化剂在动态动力学拆分还原胺化反 应中的应用范围。 据介绍，手性N-取代氨基酰胺和氨基酯是多种药物和农药的关键结构单元。该类化合物尤其是含多个 手性中心的N-取代氨基酰胺/氨基酯的高效不对称合成一直存在挑战。传统化学合成方法往往依赖苛刻 反应条件或贵金属催化剂，且难以精确控制还原胺化过程中的立体选择性。因此，开发生物合成方法具 有重要意义。 ...